Please login to the form below

Not currently logged in
Email:
Password:

Roche to buy Anadys for $230m

Roche is to acquire US-based Anadys Pharmaceuticals for $230m, developing the company's hepatitis C capabilities

Roche is to acquire US-based Anadys Pharmaceuticals for $3.70 per share – about $230m in total.

Anadys specialises in the development of oral, small molecule therapeutics for the potential treatment of hepatitis C virus infection.

The deal will see Roche take ownership of the drug candidate setrobuvir (ANA598), which is currently in a phase II study in combination with Roche's (Pegasys) pegylated interferon and (Copegus) ribavirin.

Other products in development include ANA773, which is currently at phase I trial stage for the treatment of hepatitis C as well as other chronic infections and cancer.

Jean-Jacques Garaud, global head of Roche pharmaceutical research and early development, said the acquisition would enhance the company's presence in the treatment of hepatitis C.

He said: "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics